Microfluorimetry defines early axonal damage in a rat model of optic neuritis: a novel method targeting early CNS

Martha E Stokely1, Manzoor A Bhat, Peter Koulen

  • 1Department of Pharmacology and Neuroscience, University of North Texas Health Science Center at Fort Worth, Fort Worth, TX 76107, USA.

Insights

Early autoimmune optic neuritis, a multiple sclerosis precursor, shows significant axonal damage. New methods quantify neuroinflammation, demyelination, and axonal injury, aiding the search for safer treatments.

Area of Science:

  • Neuroimmunology
  • Ophthalmology
  • Neuropathology

Background:

  • Autoimmune optic neuritis is an early sign of multiple sclerosis (MS).
  • Current MS treatments carry ocular toxicity risks, necessitating better early interventions.
  • Early detection of pathologies in optic neuritis is crucial for managing MS.

Purpose of the Study:

  • To develop a sensitive method for quantifying early pathologies in autoimmune optic neuritis.
  • To model MS-like pathologies in an animal model.
  • To identify early markers of axonal damage.

Main Methods:

  • Utilized a Brown Norway rat model of experimental autoimmune optic neuritis induced by myelin oligodendrocyte glycoprotein (MOG) peptide (35-55).
  • Employed tissue microfluorimetry to measure seven established markers of human MS pathology.
  • Assessed optic nerves 13 days post-antigen exposure.

Main Results:

  • Rats with optic neuritis showed significant neuroinflammation, immune infiltration, and demyelination.
  • Early axonal damage was identified, characterized by decreased paranodin immunoreactivity (PN-ir) and increased amyloid precursor protein immunoreactivity (APP-ir).
  • These changes indicate loss of paranodal junctions and impaired fast axonal transport.

Conclusions:

  • The developed method reliably quantifies early pathologies in autoimmune optic neuritis.
  • The findings provide a quantitative pattern of early axonal damage relevant to MS.
  • This research supports the development of safer, targeted early MS therapies.

Related Concept Videos